SummaryHigh Gleason grade prostate carcinomas are aggressive, poorly differentiated tumors that exhibit diminished estrogen receptor β (ERβ) expression. We report that a key function of ERβ and its specific ligand 5α-androstane-3β,17β-diol (3β-adiol) is to maintain an epithelial phenotype and repress mesenchymal characteristics in prostate carcinoma. Stimuli (TGF-β and hypoxia) that induce an epithelial-mesenchymal transition (EMT) diminish ERβ expression, and loss of ERβ is sufficient to promote an EMT. The mechanism involves ERβ-mediated destabilization of HIF-1α and transcriptional repression of VEGF-A. The VEGF-A receptor neuropilin-1 drives the EMT by promoting Snail1 nuclear localization. Importantly, this mechanism is manifested in h...
Emerging evidence suggests a decline of ERβ expression in various peripheral cancers. ERβ has been p...
The androgen receptor (AR) signaling pathway is one of the key pathways deregulated in prostate canc...
The long-standing challenge in the treatment of prostate cancer is to overcome therapeutic resistanc...
SummaryHigh Gleason grade prostate carcinomas are aggressive, poorly differentiated tumors that exhi...
High Gleason grade prostate cancers are aggressive. Currently, the major target for treatment is the...
Estrogen receptor β (ERβ) was first identified in the rodent prostate and is abundantly expressed in...
The estrogen receptor (ER) β variant ERβ2 is expressed in aggressive castration-resistant prostate c...
The role of ERβ in prostate cancer is unclear, although loss of ERβ is associated with aggressive di...
<div><p>The estrogen receptor (ER) β variant ERβ2 is expressed in aggressive castration-resistant pr...
SummaryThe role of ERβ in prostate cancer is unclear, although loss of ERβ is associated with aggres...
Prostate cancer (PC) is characterised by dependence upon androgen receptor (AR) as its driving oncog...
Differentiation status influences the prognosis for localized prostate cancer. In this issue of Canc...
Estrogen receptor β (ERβ) was first identified in the rodent prostate and is abundantly expressed in...
Understanding the initial mechanisms by which epithelial cells transform to an invasive phenotype is...
Background: Prostate is the site of two of the most common diseases in elderly men, BPH and Prostati...
Emerging evidence suggests a decline of ERβ expression in various peripheral cancers. ERβ has been p...
The androgen receptor (AR) signaling pathway is one of the key pathways deregulated in prostate canc...
The long-standing challenge in the treatment of prostate cancer is to overcome therapeutic resistanc...
SummaryHigh Gleason grade prostate carcinomas are aggressive, poorly differentiated tumors that exhi...
High Gleason grade prostate cancers are aggressive. Currently, the major target for treatment is the...
Estrogen receptor β (ERβ) was first identified in the rodent prostate and is abundantly expressed in...
The estrogen receptor (ER) β variant ERβ2 is expressed in aggressive castration-resistant prostate c...
The role of ERβ in prostate cancer is unclear, although loss of ERβ is associated with aggressive di...
<div><p>The estrogen receptor (ER) β variant ERβ2 is expressed in aggressive castration-resistant pr...
SummaryThe role of ERβ in prostate cancer is unclear, although loss of ERβ is associated with aggres...
Prostate cancer (PC) is characterised by dependence upon androgen receptor (AR) as its driving oncog...
Differentiation status influences the prognosis for localized prostate cancer. In this issue of Canc...
Estrogen receptor β (ERβ) was first identified in the rodent prostate and is abundantly expressed in...
Understanding the initial mechanisms by which epithelial cells transform to an invasive phenotype is...
Background: Prostate is the site of two of the most common diseases in elderly men, BPH and Prostati...
Emerging evidence suggests a decline of ERβ expression in various peripheral cancers. ERβ has been p...
The androgen receptor (AR) signaling pathway is one of the key pathways deregulated in prostate canc...
The long-standing challenge in the treatment of prostate cancer is to overcome therapeutic resistanc...